natgillin/translations-raw huggingface dataset:
For more information about treatment with Ebixa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Ebixa preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
This is a summary of the European public assessment report (EPAR) for Ebixa. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ebixa.
The most common side effects with Ebixa (seen in between 1 and 10 patients in 100) are somnolence (sleepiness), dizziness, hypertension (high blood pressure), dyspnoea (difficulty breathing), constipation, headache and drug hypersensitivity (allergy to the medicine). 
Najpogostejši neželeni učinki zdravila Ebixa (opaženi pri 1 do 10 bolnikih od 100) so somnolenca (zaspanost), omotica, hipertenzija (visok krvni tlak), dispneja (oteženo dihanje), zaprtje, glavobol in preobčutljivost (alergija na zdravilo).
However, when these results were considered along with those of the three additional studies, it was noted that the effect of Ebixa was smaller in patients with mild disease. 
Vendar pa je bilo s primerjavo teh rezultatov z rezultati treh dodatnih študij ugotovljeno, da je bil učinek zdravila Ebixa manjši pri bolnikih z blago boleznijo.
Ebixa is used to treat patients with moderate to severe Alzheimer's disease. 
Zdravilo Ebixa se uporablja za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Ebixa was more effective than placebo at controlling the symptoms of Alzheimer's disease. 
Zdravilo Ebixa je bilo pri nadzorovanju simptomov Alzheimerjeve bolezni učinkovitejše od placeba.
The tolerance and dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing treatment with Ebixa should be reassessed on a regular basis. 
Prenašanje in odmerek zdravila je treba oceniti v 3 mesecih od začetka zdravljenja, od takrat naprej pa je treba koristi zdravljenja z zdravilom Ebixa ponovno ocenjevati v rednih intervalih.
What benefit has Ebixa shown during the studies? 
Kakšne koristi je zdravilo Ebixa izkazalo med študijami?
Ebixa has been studied in three main studies including a total of 1,125 patients with Alzheimer's disease, some of whom had taken other medicines for their disease in the past. 
Zdravilo Ebixa so proučevali v treh glavnih študijah, ki so vključevale skupno 1 125 bolnikov z Alzheimerjevo boleznijo, pri čemer so nekateri izmed njih v preteklosti prejemali druga zdravila za zdravljenje te bolezni.
Ebixa was compared with placebo (a dummy treatment) over 24 to 28 weeks. 
Zdravilo Ebixa so primerjali s placebom (zdravilom brez zdravilne učinkovine) v obdobju 24 do 28 tednov.
Treatment should only be started if a caregiver is available who will regularly monitor the use of Ebixa by the patient. 
Zdravljenje se sme uvesti samo, če je na voljo negovalec, ki bo redno spremljal bolnikovo jemanje zdravila Ebixa.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ebixa. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Ebixa, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The CHMP decided that Ebixa's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Ebixa večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Ebixa should not be used in people who may be hypersensitive (allergic) to memantine hydrochloride or any of the other ingredients. 
Zdravila Ebixa ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) memantinijev klorid ali katero koli drugo sestavino zdravila.
Ebixa was also studied in three additional studies including a total of 1,186 patients with mild to severe disease. 
Zdravilo Ebixa so proučevali še v treh dodatnih študijah, ki so vključevale skupno 1 186 bolnikov z blago do hudo boleznijo.
Ebixa is also available as an oral solution, which is supplied with a pump that delivers 5 mg memantine hydrochloride with each activation. 
Zdravilo Ebixa je na voljo tudi kot peroralna raztopina z dodano črpalko, ki dovaja 5 mg memantinijevega klorida ob vsakem črpanju.
In the two studies of mild to moderate disease, patients on Ebixa had less severe symptoms after 24 weeks, as measured on the global and cognitive scores. 
V dveh študijah blage do zmerne bolezni so imeli bolniki, ki so prejemali zdravilo Ebixa, po 24 tednih manj hudih simptomov, merjeno z globalnimi in kognitivnimi merili.
What is the risk associated with Ebixa? 
Kakšna tveganja so povezana z zdravilom Ebixa?
In the study of moderately severe to severe disease, patients taking Ebixa had fewer symptoms than those taking placebo after 28 weeks, as measured on both global and functional scores. 
V študiji z bolniki z zmerno hudo do hudo boleznijo je bilo po 28 tednih pri bolnikih, ki so jemali zdravilo Ebixa, ugotovljenih manj simptomov kot pri bolnikih, ki so jemali placebo, merjeno z globalnimi in funkcionalnimi merili.
For the full list of all side effects reported with Ebixa, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Ebixa, glejte navodilo za uporabo.
Ebixa is a medicine that contains the active substance memantine hydrochloride. 
Ebixa je zdravilo, ki vsebuje zdravilno učinkovino memantinijev klorid.
The active substance in Ebixa, memantine hydrochloride, is an antidementia medicine. 
Zdravilna učinkovina zdravila Ebixa, memantinijev klorid, je zdravilo za zdravljenje demence.
Why has Ebixa been approved? 
Zakaj je bilo zdravilo Ebixa odobreno?
How has Ebixa been studied? 
Kako je bilo zdravilo Ebixa raziskano?
What is Ebixa used for? 
Za kaj se zdravilo Ebixa uporablja?
How does Ebixa work? 
Kako zdravilo Ebixa deluje?
What is Ebixa? 
Kaj je zdravilo Ebixa?
How is Ebixa used? 
Kako se zdravilo Ebixa uporablja?
This summary was last updated in 02-2017. 
Povzetek je bil nazadnje posodobljen 02-2017.
Metformin has been available in the EU since the 1950s. 
Metformin je v EU na voljo od petdesetih let prejšnjega stoletja.
Doses are adjusted as necessary. 
Odmerka se po potrebi prilagodita.
Supportive evidence was provided from several further studies. 
Več nadaljnjih študij je ponudilo podporne dokaze.
What measures are being taken to ensure the safe and effective use of Synjardy? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Synjardy?
The European Commission granted a marketing authorisation valid throughout the European Union for Synjardy on 27 May 2015. 
Evropska komisija je dovoljenje za promet z zdravilom Synjardy, veljavno po vsej Evropski uniji, izdala 27. maja 2015.
• liver impairment, or problems with alcoholism or alcohol intoxication. 
• jetrno okvaro ali težavami z alkoholizmom ali zastrupitvijo z alkoholom.
The full EPAR and risk management plan summary for Synjardy can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Synjardy sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Some of these were continuations of the main studies that suggested the benefits of the combination continued with longer therapy. 
Med nekatere od njih spadajo nadaljevanje glavnih študij, v katerih so zabeležili, da so se koristi kombinacije nadaljevale z daljšim zdravljenjem.
This is a summary of the European public assessment report (EPAR) for Synjardy. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Synjardy.
Synjardy must not be used in patients with: 
Zdravila Synjardy ne smejo uporabljati bolniki z:
Empagliflozin has been authorised in the EU under the trade name Jardiance since 2014. 
Empagliflozin je s tržnim imenom Jardiance v EU odobren od leta 2014.
This leads to a high level of glucose in the blood. 
To vodi do visoke ravni glukoze v krvi.
• in patients who are already taking metformin and empagliflozin as separate tablets. 
• pri bolnikih, ki že jemljejo metformin in empagliflozin v obliki ločenih tablet.
It is not intended to provide practical advice on how to use Synjardy. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Synjardy's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Synjardy večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The main measure of effectiveness was the reduction in the level of a substance in the blood called glycosylated haemoglobin (HbA1c) after 24 weeks of treatment. 
Glavno merilo učinkovitosti je bilo zmanjšanje količine snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), po 24 tednih zdravljenja.
• metabolic acidosis (when the body produces more acid than it gets rid of) or diabetic pre-coma (dangerous complications of diabetes); 
• metabolično acidozo (kadar telo tvori več kisline kot je izloči) ali diabetično predkomo (nevarnima zapletoma sladkorne bolezni);
In addition, the results indicated that the combination was associated with a beneficial decrease in body weight and blood pressure. 
Poleg tega so rezultati pokazali, da je zdravljenje s kombinacijo zdravil povezano s koristnim zmanjšanjem telesne mase in krvnega tlaka.
Because of concerns about the balance of benefit and risk in patients with reduced kidney function taking the fixed-dose combination, the CHMP recommended restricting its use in these patients. 
Zaradi pomislekov glede razmerja med tveganji in koristmi pri bolnikih z zmanjšanim delovanjem ledvic, ki jemljejo fiksno kombinacijo odmerkov, je odbor CHMP priporočil omejitev njegove uporabe pri teh bolnikih.
Other information about Synjardy 
Druge informacije o zdravilu Synjardy
Among these, in patients who were also taking metformin (the other active substance in Synjardy), the three major cardiovascular events occurred in 9.9% (344 out of 3,459) of patients receiving empagliflozin and in 10.9% (189 out of 1,734) of patients receiving placebo. 
Med njimi so se pri bolnikih, ki so jemali tudi metformin (drugo zdravilno učinkovino zdravila Synjardy), trije glavni kardiovaskularni dogodki pojavili pri 9,9 % (344 od 3 459) bolnikov, ki so prejemali empagliflozin, in 10,9 % (189 od 1 734) bolnikov, ki so prejemali placebo.
What are the risks associated with Synjardy? 
Kakšna tveganja so povezana z zdravilom Synjardy?
What benefits of Synjardy have been shown in studies? 
Kakšne koristi je zdravilo Synjardy izkazalo v študijah?
What is Synjardy and what is it used for? 
Kaj je zdravilo Synjardy in za kaj se uporablja?
The recommended dose of Synjardy is one tablet twice a day with meals, and treatment is normally started with a tablet that supplies the dose of metformin the patient is already taking, together with the lowest dose (5 mg) of empagliflozin. 
Priporočeni odmerek zdravila Synjardy je ena tableta dvakrat na dan ob obrokih, zdravljenje pa se navadno začne s tableto, ki vsebuje odmerek metformina, ki ga bolnik že jemlje, in najmanjši odmerek (5 mg) empagliflozina.
Similar benefits were seen in the studies regardless of the other diabetes medicines being taken. 
V študijah so opazili podobne koristi, ne glede na drugo zdravilo za zdravljenje sladkorne bolezni, ki so ga jemali bolniki.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Synjardy have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Synjardy upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Synjardy is used: 
Zdravilo Synjardy se uporablja:
Why is Synjardy approved? 
Zakaj je bilo zdravilo Synjardy odobreno?
The benefits of empagliflozin in combination with metformin have been shown in 3 main studies involving 1,679 patients with type 2 diabetes whose blood sugar was not adequately controlled by metformin, alone or combined with other diabetes medicines (such as pioglitazone or a type of diabetes medicine called a sulphonylurea). 
Koristi kombinacije empagliflozina in metformina so dokazali v treh glavnih študijah, ki so vključevale 1 679 bolnikov s sladkorno boleznijo tipa 2, pri katerih sladkor v krvi ni bil zadostno uravnan s samostojnim metforminom ali metforminom v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni (kot sta pioglitazon ali druga vrsta zdravila za zdravljenje sladkorne bolezni, sulfonilsečnina).
For more information about treatment with Synjardy, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Synjardy preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
• severely reduced kidney function or conditions that could affect the kidneys such as dehydration, severe infection or a steep fall in blood pressure; 
• močno zmanjšanim delovanjem ledvic ali stanji, ki lahko vplivajo na ledvice, kot so dehidracija, huda okužba ali nenaden padec krvnega tlaka;
Metformin works mainly by reducing the production of glucose in the body and reducing its absorption from the gut. 
Metformin učinkuje predvsem tako, da zmanjšuje tvorjenje glukoze v telesu in njeno absorbcijo iz črevesa.
In those receiving empagliflozin, cardiovascular events occurred in 10.5% (490 out of 4,687) of patients compared with 12.1% (282 out of 2,333) of patients receiving placebo. 
Kardiovaskularni dogodki so se pojavili pri 10,5 % (490 od 4 687) bolnikov, ki so prejemali empagliflozin, v primerjavi z 12,1 % (282 od 2 333)
• a condition that could reduce the supply of oxygen to body tissues (such as in patients with worsening heart failure, recent heart attack, breathing difficulty or a steep fall in blood pressure); 
• obolenjem, ki lahko zmanjša dovajanje kisika v tkiva (npr. pri bolnikih, pri katerih se slabša srčno popuščanje, pri tistih, ki so pred kratkim doživeli srčni napad, imajo oteženo dihanje ali nenaden padec krvnega tlaka);
In type 2 diabetes the body does not make enough insulin to control the level of glucose (sugar) in the blood or the body is unable to use insulin effectively. 
Pri sladkorni bolezni tipa 2 telo ne proizvaja dovolj insulina za vzdrževanje primerne ravni glukoze (sladkorja) v krvi ali ga telo ne more učinkovito izrabiti.
• in patients whose diabetes is not sufficiently controlled by metformin alone; 
• pri bolnikih, pri katerih sladkorna bolezen ni zadovoljivo uravnana samo z metforminom;
For practical information about using Synjardy, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Synjardy naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Another main study showed that adding empagliflozin (one of the active substances of Synjardy) to usual treatment reduced adverse cardiovascular (heart and blood vessels) effects. 
Druga glavna študija je pokazala, da dodajanje empagliflozina (ene od zdravilnih učinkovin zdravila Synjardy) običajnemu zdravljenju, zmanjšuje neželene kardiovaskularne učinke (učinke na srce in ožilje).
Empagliflozin works by blocking a protein in the kidneys (called sodium-glucose co-transporter 2 or SGLT2). 
Empagliflozin deluje tako, da zavira beljakovino v ledvicah (imenovano natrijev glukozni koprenašalec 2 ali SGLT2).
The CHMP concluded that the medicine could help produce a clinically meaningful reduction in blood glucose in patients with type 2 diabetes, and the benefits and risks were in line with those of the individual active substances. 
Sklenil je, da lahko zdravilo pomaga pri klinično pomembnem znižanju ravni glukoze v krvi pri bolnikih s sladkorno boleznijo tipa 2 in da so bile koristi ter tveganja skladna s koristmi in tveganji pri posameznih zdravilnih učinkovinah.
Studies also indicated Synjardy was as effective as empagliflozin and metformin taken separately, and that the combination helped reduce HbA1c when added to treatment including insulin. 
Študije so prav tako pokazale, da je zdravilo Synjardy enako učinkovito kot ločeno jemanje empagliflozina in metformina ter da je kombinacija pomagala znižati raven HbA1c, če je bila dodana zdravljenju, ki vključuje insulin.
Synjardy was also shown to reduce cardiovascular events in patients with type 2 diabetes who already had cardiovascular disease. 
Zabeležili so tudi, da je zdravilo Synjardy zmanjšalo pojavnost kardiovaskularnih dogodkov pri bolnikih s sladkorno boleznijo tipa 2, ki so kardiovaskularno obolenje že imeli.
Synjardy is available as tablets containing 5 or 12.5 mg of empagliflozin with 850 or 1,000 mg of metformin, and can only be obtained with a prescription. 
Zdravilo Synjardy je na voljo v obliki tablet, ki vsebujejo 5 ali 12,5 mg empagliflozina in 850 ali 1 000 mg metformina.
• in combination with other diabetes medicines in patients whose diabetes is not sufficiently controlled on these medicines plus metformin; 
• v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni pri bolnikih, pri katerih sladkorna bolezen ni zadovoljivo uravnana s temi zdravili v kombinaciji z metforminom;
Synjardy is a diabetes medicine used with diet and exercise to treat adults with type 2 diabetes. 
Synjardy je zdravilo za zdravljenje sladkorne bolezni, ki se skupaj z dieto in telesno vadbo uporablja za zdravljenje odraslih s sladkorno boleznijo tipa 2.
Overall, the additional reduction was 0.58 percentage points with a combination providing 5 mg of empagliflozin twice daily, and 0.62 percentage points with the 12.5 mg dose, and these reductions were considered clinically relevant. 
Dodatno zmanjšanje pri kombinaciji s 5 mg empagliflozina dvakrat na dan je bilo 0,58 odstotne točke, pri kombinaciji z 12,5 mg pa 0,62 odstotne točke.
For the full list of all side effects reported with Synjardy, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Synjardy, glejte navodilo za uporabo.
The most common side effects with Synjardy are hypoglycaemia (low blood sugar levels) when the medicine is taken with a sulphonylurea or insulin, infections of the urinary tract and genitals, and increased urination. 
Najpogostejši neželeni učinki zdravila Synjardy so hipoglikemija (nizke ravni sladkorja v krvi), kadar se to zdravilo jemlje skupaj s sulfonilsečnino ali insulinom, okužbe sečil in spolovil ter povečano izločanje urina.
The studies showed a greater reduction in HbA1c when empagliflozin plus metformin was given, compared with placebo plus metformin. 
V študijah so pokazali večje zmanjšanje vrednosti HbA1c pri kombinaciji empagliflozina in metformina kot pri kombinaciji placeba in metformina.
If Synjardy is used in combination with insulin or a sulphonylurea (a medicine that increases the body's production of insulin), the doses of these medicines may need to be lowered to avoid hypoglycaemia (low blood sugar levels). 
Če se zdravilo Synjardy uporablja v kombinaciji z insulinom ali sulfonilsečnino (zdravilom, ki spodbuja izločanje insulina), bo za preprečitev hipoglikemije (nizkih ravni sladkorja v krvi) morda treba njun odmerek zmanjšati.
The two active substances in Synjardy, empagliflozin and metformin, work in different ways to lower blood glucose, and thus to control symptoms of the disease. 
Zdravilni učinkovini v zdravilu Synjardy, empagliflozin in metformin, glukozo v krvi zmanjšujeta na različna načina in tako nadzorujeta simptome te bolezni.
It contains the active substances empagliflozin and metformin. 
Vsebuje zdravilni učinkovini, empagliflozin in metformin.
How is Synjardy used? 
Kako se zdravilo Synjardy uporablja?
How does Synjardy work? 
Kako zdravilo Synjardy deluje?
The studies compared the effect of empagliflozin plus metformin versus placebo (a dummy treatment) with metformin. 
V študijah so primerjali učinek kombinacije empagliflozina in metformina s kombinacijo placeba (zdravila brez zdravilne učinkovine) in metformina.
By blocking the action of SGLT2, empagliflozin causes more glucose to be removed in the urine, thereby reducing the levels of glucose in the blood. 
Empagliflozin z zaviranjem delovanja koprenašalca SGLT2 povzroči večje izločanje glukoze z urinom, kar zniža njene ravni v krvi.
It should be used in combination with safer sex practices, such as use of condoms. 
Uporabljati bi se moralo v kombinaciji z varnejšimi spolnimi praksami, na primer uporabo kondomov.
This means that it is converted into tenofovir in the body. 
To pomeni, da se v tenofovir pretvori v telesu.
Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect. 
Dve zdravili sta bioekvivalentni, kadar dosegata enake ravni učinkovine v telesu in imata zato po pričakovanjih enak učinek.
Further information on Emtricitabine/Tenofovir disoproxil Zentiva can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/emtricitabinetenofovir-disoproxil-zentiva. 
Nadaljnje informacije o zdravilu Emtricitabin/dizoproksiltenofovirat Zentiva so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/emtricitabinetenofovir-disoproxil-zentiva.
Emtricitabine/Tenofovir disoproxil Zentiva received a marketing authorisation valid throughout the EU on 9 November 2016. 
Za zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva je bilo 9. novembra 2016 izdano dovoljenje za promet, veljavno po vsej EU.
Both active substances have been authorised in the EU since the early 2000s: emtricitabine was authorised as Emtriva in 2003, and tenofovir disoproxil was authorised as Viread in 2002. 
Za obe učinkovini je bilo v začetku 21. stoletja izdano dovoljenje za promet v EU: emtricitabin je odobren kot zdravilo Emtriva od leta 2003, dizoproksiltenofovirat pa kot zdravilo Viread od leta 2002.
The company also carried out a study that showed that it is ‘bioequivalent' to the reference medicine. 
Opravilo je tudi študijo, ki je pokazala, da je zdravilo bioekvivalentno referenčnemu zdravilu.
In addition it may be used from the age of 12 years in adolescents with HIV that is resistant to first-line treatments or who cannot take them because of side effects. 
Poleg tega se lahko uporablja tudi pri mladostnikih, starejših od 12 let, ki so okuženi z virusom HIV in so odporni proti zdravilom prve izbire ali teh zaradi neželenih učinkov ne morejo jemati.
The European Medicines Agency concluded that, in accordance with EU requirements, Emtricitabine/Tenofovir disoproxil Zentiva has been shown to have comparable quality and to be bioequivalent to Truvada. 
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva primerljivo raven kakovosti kot referenčno zdravilo Truvada ter da mu je bioekvivalentno.
Healthcare professionals will also receive a brochure and reminder card to hand out to individuals receiving the medicine for pre-exposure prophylaxis. 
Zdravstveni delavci bodo prav tako prejeli brošuro in opozorilno kartico za posameznike, ki zdravilo jemljejo za predekspozicijsko profilakso.
Because Emtricitabine/Tenofovir disoproxil Zentiva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.